Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FK962 in Mild to Moderate Alzheimer's Disease
NCT00087724Phase 2Terminated
- Sponsor
- Astellas Pharma
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of FK962 in Alzheimer's disease (AD), sponsored by Astellas Pharma. Started Jul 2004; status: terminated.
02
Drugs
FK962
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00087724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087724.